D M Bunting1, J R Steel, C S Holgate, R M Watkins. 1. Primrose Breast Care Centre, Derriford Hospital, Derriford Road, Plymouth, PL6 8DH, UK. davidbunting@doctors.org.uk
Abstract
AIMS: Radial scars (RS)/complex sclerosing lesions (CSL) are rare, benign breast lesions of unknown aetiology. Associations with breast cancer have been suggested particularly with larger lesions. This study aims to identify the risk of developing subsequent breast cancer after excision of a benign RS/CSL with respect to lesion size and compared to expected rates in the normal UK population. METHODS: A prospective cohort analysis was performed on patients diagnosed with RS/CSL in benign, open breast biopsy specimens over a 20-year period. The rate of subsequent breast cancer development was compared to expected rates in the normal UK population. Subjects were divided into two groups according to lesion size and the rates of subsequent breast cancer compared. RESULTS: 149 women without proliferative breast disease were followed for an average of 68 months. Five women developed subsequent cancer, equating to a rate of 0.84% per year. This compares to 0.32% per year in the normal population (RR 2.6, 95% CI 0.86-6.0). There were two subsequent cancers in the RS group and three subsequent cancers in the CSL group, P = 0.64. CONCLUSIONS: The study finds no evidence to suggest that lesions greater than 10 mm (CSL) have any greater risk of developing cancer after excision than those below 10 mm (RS). Women treated for RS/CSL do not need any additional follow-up beyond routine mammographic breast screening. Additional surveillance should only be performed if there is associated pathology indicating an increased risk of subsequent malignancy.
AIMS: Radial scars (RS)/complex sclerosing lesions (CSL) are rare, benign breast lesions of unknown aetiology. Associations with breast cancer have been suggested particularly with larger lesions. This study aims to identify the risk of developing subsequent breast cancer after excision of a benign RS/CSL with respect to lesion size and compared to expected rates in the normal UK population. METHODS: A prospective cohort analysis was performed on patients diagnosed with RS/CSL in benign, open breast biopsy specimens over a 20-year period. The rate of subsequent breast cancer development was compared to expected rates in the normal UK population. Subjects were divided into two groups according to lesion size and the rates of subsequent breast cancer compared. RESULTS: 149 women without proliferative breast disease were followed for an average of 68 months. Five women developed subsequent cancer, equating to a rate of 0.84% per year. This compares to 0.32% per year in the normal population (RR 2.6, 95% CI 0.86-6.0). There were two subsequent cancers in the RS group and three subsequent cancers in the CSL group, P = 0.64. CONCLUSIONS: The study finds no evidence to suggest that lesions greater than 10 mm (CSL) have any greater risk of developing cancer after excision than those below 10 mm (RS). Women treated for RS/CSL do not need any additional follow-up beyond routine mammographic breast screening. Additional surveillance should only be performed if there is associated pathology indicating an increased risk of subsequent malignancy.
Authors: Aziza Nassar; Amy L Conners; Betul Celik; Sarah M Jenkins; Carin Y Smith; Tina J Hieken Journal: Ann Diagn Pathol Date: 2014-12-20 Impact factor: 2.090
Authors: Michele L Cote; Julie J Ruterbusch; Barra Alosh; Sudeshna Bandyopadhyay; Elizabeth Kim; Bassam Albashiti; Bashar Sharaf Aldeen; Derek C Radisky; Marlene H Frost; Daniel W Visscher; Lynn C Hartmann; Warzecha Hind Nassar; Rouba Ali-Femhi Journal: Cancer Prev Res (Phila) Date: 2012-10-19
Authors: David Chelmow; Mark D Pearlman; Amy Young; Laura Bozzuto; Sandra Dayaratna; Myrlene Jeudy; Mallory E Kremer; Dana Marie Scott; Julia Sage O'Hara Journal: Obstet Gynecol Date: 2020-06 Impact factor: 7.623